BriaCell Therapeutics (BCTX) vs Nasus Pharma (NSRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BriaCell Therapeutics (BCTX) has outperformed Nasus Pharma (NSRX) over the past year, losing 61.7% versus a loss of 68.4%. Nasus Pharma is the larger company by market cap ($26.8 million vs $26.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCTX | NSRX |
|---|---|---|
| Share price | $3.06 | $2.29 |
| Market cap | $26.72M | $26.82M |
| 1-day change | -3.32% | -10.20% |
| YTD return | -56.96% | -74.97% |
| 1-year return | -61.75% | -68.41% |
| 5-year return | -97.00% | — |
| EPS (TTM) | $-6.97 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.24B |
| Net income (latest FY) | $-34.90M | $-5.86M |
| Operating margin | — | -0.40% |
| Net margin | — | -0.47% |
| 52-week high | $13.09 | $9.50 |
| 52-week low | $2.60 | $1.98 |
| Distance from 52-week high | -76.62% | -75.89% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +758.95% |
| Average volume | 250.81K | 16.80K |
| Shares outstanding | 8.73M | 11.71M |
| Employees | — | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
BCTX vs NSRX FAQ
Which is bigger, BriaCell Therapeutics or Nasus Pharma?
Nasus Pharma (NSRX) is larger, with a market capitalization of $26.82M compared with $26.72M for BriaCell Therapeutics (BCTX).
Which stock has performed better over the past year, BCTX or NSRX?
BCTX returned -61.75% over the past 12 months, compared with -68.41% for NSRX (price return, excluding dividends). Past performance does not predict future results.
Are BriaCell Therapeutics and Nasus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.